2022
DOI: 10.1016/j.lungcan.2021.12.014
|View full text |Cite
|
Sign up to set email alerts
|

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2
1
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 13 publications
0
2
0
Order By: Relevance
“…This approach has been applied to block similar tyrosine-kinase receptors, such as vascular endothelial growth factor (VEGF) with mAbs (bevacizumab); however, drugs able to speci cally target EGF have been scarcely developed. Along this line, a method based on active immunotherapy (EGF vaccine) has been developed and is currently in clinical trials [14]. In vitro, sera from the vaccinated patients-but not from control patients-blocked the EGF-EGFR interaction as well as EGFR phosphorylation, thus con rming the mechanism of action of the vaccine.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This approach has been applied to block similar tyrosine-kinase receptors, such as vascular endothelial growth factor (VEGF) with mAbs (bevacizumab); however, drugs able to speci cally target EGF have been scarcely developed. Along this line, a method based on active immunotherapy (EGF vaccine) has been developed and is currently in clinical trials [14]. In vitro, sera from the vaccinated patients-but not from control patients-blocked the EGF-EGFR interaction as well as EGFR phosphorylation, thus con rming the mechanism of action of the vaccine.…”
Section: Discussionmentioning
confidence: 99%
“…Along this line, we showed in a previous study that antibodies raised by the EGF vaccine enhanced the e cacy of TKIs such as ge tinib and delayed the emergence of resistance in cellular models of NSCLC [13]. Furthermore, a recent phase Ib clinical trial has evaluated the combination of rst-line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC [14].…”
Section: Introductionmentioning
confidence: 88%